“हारेगा डेंगू, हराएंगे हम” campaign launched to spread awareness regarding dengue prevention and control The United States Agency for International Development (USAID) and Takeda Biopharmaceuticals India Private Limited (formerly Baxalta Bioscience India Private Limited) have launched a new campaign called "Haarega Dengue Haraenge Hum (We
Mankind Pharma Limited (BSE: 543904 | NSE: MANKIND) and Takeda Pharmaceutical Company Limited signed a Non-Exclusive Patent License Agreement for commercialising 'Vonoprazan' in the Indian market. The agreement allows Mankind Pharma to launch the novel drug for treating Gastroesophageal Reflux Disease (GERD) under its trademark. Vonoprazan
The appointment is effective as of May 16, 2024. In her new role, Annapurna will lead the Company in India, ensuring patient access to its highly innovative medicines and vaccines, and advancing valuable collaborations to contribute to the growing domestic healthcare and pharmaceutical market. (TSE:4502/NYSE:TAK) Takeda Biopharmaceuticals
Biological E. Limited (BE) to Manufacture Up to 50 Million Doses of QDENGA Per Year, Accelerating Takeda’s Ability to Deliver 100 Million Doses Per Year by 2030 At the Latest Addresses the Specific Need to Offer Multi-Dose Vials for National Immunization Programs to
New strategic partnership will scale-up manufacturing capacity to support global supply of dengue vaccine and expands Takeda's footprint in vaccine manufacturing The strategic partnership will deliver potentially up to 50 million doses per year by 2030 to address global public health need Dengue is a
The local-to-global initiative will support healthcare innovation and technological advancement for comprehensive solutions catering to healthcare needs Besides supporting healthcare startups, the partnership will also contribute to India’s aspiration of emerging as a US$300 billion Bio-economy by 2030
The intervention will benefit ~60,000 women and children in selected areas of Delhi This initiative will prioritize nutrition outcomes by deepening partnership with the government to strengthen health and ICDS systems to promote evidence-based, sustainable, multi-sectoral actions for improved quality of health and nutrition
Takeda Biopharmaceuticals India Private Limited (formerly known as Baxalta Bioscience India Private Limited), a global values-based, R&D-driven biopharmaceutical leader conducted dissemination of its public health initiatives in strengthening the health system for rare diseases (RD) in India. These initiatives aim to improve access to healthcare
Sunrise is built on four elements i.e., Awareness, Screening & Diagnosis, Treatment, and Maintenance Support Availability of a toll-free help line number 1800 103 4260 to provide coordination & counselling support for patients The initiative aims to drive HAE awareness through patient education, and timely
Takeda Biopharmaceuticals India Private Limited (formerly known as Baxalta Bioscience India Pvt. Ltd.), a global values-based, R&D-driven biopharmaceutical leader, has been certified as a Great Place To Work® in India (March 2023 - March 2024). This certification has been awarded second time in a row to
